Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2002026703) CARBAMIC ACID COMPOUNDS COMPRISING AN ETHER LINKAGE AS HDAC INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2002/026703 International Application No.: PCT/GB2001/004327
Publication Date: 04.04.2002 International Filing Date: 27.09.2001
Chapter 2 Demand Filed: 26.04.2002
IPC:
C07C 259/06 (2006.01) ,C07C 323/60 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
259
Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
04
without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
06
having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
323
Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
50
containing thio groups and carboxyl groups bound to the same carbon skeleton
51
having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
60
with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
Applicants:
WATKINS, Clare, J. [GB/GB]; GB (UsOnly)
ROMERO MARTIN, Maria Rosario [ES/GB]; GB (UsOnly)
FINN, Paul, W. [GB/GB]; GB (UsOnly)
KALVINSH, Ivars [LV/LV]; LV (UsOnly)
LOZA, Einars [LV/LV]; LV (UsOnly)
LOLYA, Daina [LV/LV]; LV (UsOnly)
STARCHENKOV, Igor [--/LV]; LV (UsOnly)
BOKALDERE, Rasma, Melita [LV/LV]; LV (UsOnly)
SEMENIKHINA, Valentina [--/LV]; LV (UsOnly)
HARRIS, C., John [GB/GB]; GB (UsOnly)
DUFFY, James, E., S. [GB/GB]; GB (UsOnly)
PROLIFIX LIMITED [GB/GB]; 91 Milton Park Abingdon, Oxfordshire OX14 4RY, GB (AllExceptUS)
Inventors:
WATKINS, Clare, J.; GB
ROMERO MARTIN, Maria Rosario; GB
FINN, Paul, W.; GB
KALVINSH, Ivars; LV
LOZA, Einars; LV
LOLYA, Daina; LV
STARCHENKOV, Igor; LV
BOKALDERE, Rasma, Melita; LV
SEMENIKHINA, Valentina; LV
HARRIS, C., John; GB
DUFFY, James, E., S.; GB
Agent:
ARMITAGE, Ian, M. ; Mewburn Ellis York House 23 Kingsway London, Greater London WC2B 6HP, GB
Priority Data:
0023983.029.09.2000GB
Title (EN) CARBAMIC ACID COMPOUNDS COMPRISING AN ETHER LINKAGE AS HDAC INHIBITORS
(FR) COMPOSES D'ACIDE CARBAMIQUE COMPRENANT UNE LIAISON ETHER ET UTILES EN TANT QU'INHIBITEURS DE HDAC
Abstract:
(EN) This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula(I) wherein: A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is an amide linkage selected from: -NR1C(=O)- and -C(=O)NR1-; R1 is an amido substituent; X is an ether heteroatom, and is -O- or -S-; and, R2 and R3 are each independently an ether group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.
(FR) L'invention concerne certains composés d'acide carbamique, actifs, inhibant l'activité de HDAC (histone désacétylase) et possédant la formule suivante (I) dans laquelle A représente un groupe aryle, Q1 représente une liaison covalente ou un groupe leader aryle, J représente une liaison amide choisie entre -NR1C(=O)- et -C(=O)NR1-, R1 représente un substituant amido, X représente un hétéroatome d'éther et représente -O- ou -S-, et R2 et R3 représentent chacun indépendamment un groupe éther. L'invention concerne également des sels, solvates, amides, esters, éthers, formes chimiquement protégées, et promédicaments de ces composés, et elle concerne encore des compositions pharmaceutiques comprenant de tels composés, ainsi que l'utilisation de ces composés et compositions, à la fois in vitro et in vivo, pour inhiber HDAC et, par exemple, pour inhiber des désordres prolifératifs, tels que le cancer et le psoriasis.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)